TY - JOUR
T1 - Reduction of monocyte chemoattractant protein 1 and macrophage migration inhibitory factor by a polyphenol-rich extract in subjects with clustered cardiometabolic risk factors
AU - Broekhuizen, Lysette N.
AU - van Wijk, Diederik F.
AU - Vink, Hans
AU - Stalmach, A.
AU - Crozier, A.
AU - Hutten, Barbara A.
AU - Kastelein, John J. P.
AU - Hugenholtz, Paul G.
AU - Koenig, Wolfgang
AU - Stroes, Erik S. G.
PY - 2011/11
Y1 - 2011/11
N2 - Inflammation is a hallmark of the metabolic syndrome, which also contributes to a pro-atherogenic state. NF-kappa B activation, a critical step in regulating inflammatory reactions, can be inhibited by polyphenol (PF) extracts, at least in vitro. In the present study, we set out to study whether a PF-rich extract could attenuate the chronic inflammatory state and/or an acute immune response in vivo in subjects with clustered metabolic risk factors. A commercially available, PF-rich extract (500mg daily) or placebo was administered for 4 weeks to thirty-four subjects with two or more metabolic risk factors using a randomised, double-blind, cross-over design. During the final study visit, an acute inflammatory challenge (lipopolysaccharide (LPS) 1 ng/kg body weight) was administered to a random subgroup of subjects (PF-rich extract (n 12) and placebo (n 12)). The PF-rich extract modestly reduced the inflammatory chemokines monocyte chemoattractant protein 1 (MCP-1) and macrophage migration inhibitory factor (MIF) (MCP-1 26.5% (PF, median 116 (interquartile range 97-136) pg/ml v. placebo, median 124 (interquartile range 105-153) pg/ml; P
AB - Inflammation is a hallmark of the metabolic syndrome, which also contributes to a pro-atherogenic state. NF-kappa B activation, a critical step in regulating inflammatory reactions, can be inhibited by polyphenol (PF) extracts, at least in vitro. In the present study, we set out to study whether a PF-rich extract could attenuate the chronic inflammatory state and/or an acute immune response in vivo in subjects with clustered metabolic risk factors. A commercially available, PF-rich extract (500mg daily) or placebo was administered for 4 weeks to thirty-four subjects with two or more metabolic risk factors using a randomised, double-blind, cross-over design. During the final study visit, an acute inflammatory challenge (lipopolysaccharide (LPS) 1 ng/kg body weight) was administered to a random subgroup of subjects (PF-rich extract (n 12) and placebo (n 12)). The PF-rich extract modestly reduced the inflammatory chemokines monocyte chemoattractant protein 1 (MCP-1) and macrophage migration inhibitory factor (MIF) (MCP-1 26.5% (PF, median 116 (interquartile range 97-136) pg/ml v. placebo, median 124 (interquartile range 105-153) pg/ml; P
KW - Flow-mediated dilation
KW - Polyphenols
KW - Inflammation
KW - Cardiometabolic risk factors
KW - Monocyte chemoattractant protein 1
U2 - 10.1017/S0007114511002431
DO - 10.1017/S0007114511002431
M3 - Article
C2 - 21733322
SN - 0007-1145
VL - 106
SP - 1416
EP - 1422
JO - British Journal of Nutrition
JF - British Journal of Nutrition
IS - 9
ER -